{"name":"Merck KGaA, Darmstadt, Germany","slug":"merck-kgaa-darmstadt-germany","ticker":"","exchange":"","domain":"merckkgaadarmstadtgermany.com","description":"","hq":"Darmstadt","founded":0,"employees":"","ceo":"Belén Garijo","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-12-30","label":"Cysticide Phase 2 readout (Brain Cysticercosis)","drug":"Cysticide","drugSlug":"cysticide","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":27,"colorKey":"oncology","drugs":[{"name":"Colposeptine","genericName":"Colposeptine","slug":"colposeptine","indication":"Other","status":"marketed"},{"name":"AS902330","genericName":"AS902330","slug":"as902330","indication":"Other","status":"phase_1"},{"name":"F0434","genericName":"F0434","slug":"f0434","indication":"Other","status":"phase_3"},{"name":"Follitropin beta liquid formulation","genericName":"Follitropin beta liquid formulation","slug":"follitropin-beta-liquid-formulation","indication":"Infertility in women undergoing assisted reproductive technology (ART)","status":"phase_3"},{"name":"Gonalef® (Follitropin alfa)","genericName":"Gonalef® (Follitropin alfa)","slug":"gonalef-follitropin-alfa","indication":"Infertility in women undergoing assisted reproductive technology (ART)","status":"phase_3"},{"name":"Pergoveris®","genericName":"Pergoveris®","slug":"pergoveris","indication":"Other","status":"marketed"},{"name":"Reference GIR","genericName":"Reference GIR","slug":"reference-gir","indication":"Other","status":"phase_1"},{"name":"Saizen® B","genericName":"Saizen® B","slug":"saizen-b","indication":"Growth hormone deficiency in children","status":"phase_3"},{"name":"Urinary-hCG","genericName":"Urinary-hCG","slug":"urinary-hcg","indication":"Hypogonadism in males","status":"phase_3"},{"name":"r-hGH","genericName":"r-hGH","slug":"r-hgh","indication":"Other","status":"marketed"},{"name":"Cetrorelix acetate and Follitropin alfa","genericName":"Cetrorelix acetate and Follitropin alfa","slug":"cetrorelix-acetate-and-follitropin-alfa","indication":"Ovarian stimulation in assisted reproduction","status":"phase_2"},{"name":"Cisticid","genericName":"Cisticid","slug":"cisticid","indication":"Other","status":"phase_1"},{"name":"Follitropin alfa liquid formulation","genericName":"Follitropin alfa liquid formulation","slug":"follitropin-alfa-liquid-formulation","indication":"Infertility in women undergoing assisted reproductive technology (ART) / in vitro fertilization (IVF)","status":"phase_3"},{"name":"GONAL f® prefilled pen","genericName":"GONAL f® prefilled pen","slug":"gonal-f-prefilled-pen","indication":"Other","status":"marketed"},{"name":"GONAL-f®","genericName":"GONAL-f®","slug":"gonal-f","indication":"Other","status":"marketed"},{"name":"GnRH antagonist","genericName":"GnRH antagonist","slug":"gnrh-antagonist","indication":"Other","status":"marketed"},{"name":"Gonal -f® [r-hFSH]","genericName":"Gonal -f® [r-hFSH]","slug":"gonal-f-r-hfsh","indication":"Other","status":"marketed"},{"name":"Kuvan®","genericName":"Kuvan®","slug":"kuvan","indication":"Phenylketonuria (PKU) in patients with BH4-responsive mutations","status":"marketed"},{"name":"Luveris®","genericName":"Luveris®","slug":"luveris","indication":"Infertility in women with profound LH deficiency undergoing assisted reproductive technology","status":"marketed"},{"name":"MSJ-0011","genericName":"MSJ-0011","slug":"msj-0011","indication":"Other","status":"phase_3"},{"name":"Micronised Progesterone","genericName":"Micronised Progesterone","slug":"micronised-progesterone","indication":"Other","status":"phase_3"},{"name":"Ovitrelle® [r-hCG alfa]","genericName":"Ovitrelle® [r-hCG alfa]","slug":"ovitrelle-r-hcg-alfa","indication":"Final oocyte maturation induction in women undergoing assisted reproductive technology (ART) such as in vitro fertilization (IVF)","status":"marketed"},{"name":"Placebo - IR Prednisone","genericName":"Placebo - IR Prednisone","slug":"placebo-ir-prednisone","indication":"Control arm in Phase 3 clinical trial of immediate-release prednisone","status":"phase_3"},{"name":"Placebo - MR Prednisone","genericName":"Placebo - MR Prednisone","slug":"placebo-mr-prednisone","indication":"Control arm in Phase 3 clinical trials of modified-release prednisone formulations","status":"phase_3"},{"name":"Placebo and Saizen®","genericName":"Placebo and Saizen®","slug":"placebo-and-saizen","indication":"Growth hormone deficiency (likely indication based on Saizen® approved uses)","status":"phase_3"},{"name":"Saizen® A","genericName":"Saizen® A","slug":"saizen-a","indication":"Growth hormone deficiency in children","status":"phase_3"},{"name":"urinary hCG (u-hCG)","genericName":"urinary hCG (u-hCG)","slug":"urinary-hcg-u-hcg","indication":"Pregnancy confirmation","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"neuroscience","drugs":[{"name":"IR Prednisone","genericName":"IR Prednisone","slug":"ir-prednisone","indication":"Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus, vasculitis)","status":"phase_3"},{"name":"Analogous GnRH antagonist","genericName":"Analogous GnRH antagonist","slug":"analogous-gnrh-antagonist","indication":"Advanced prostate cancer (hormone-sensitive)","status":"phase_2"},{"name":"Cetuximab + concomitant boost radiotherapy","genericName":"Cetuximab + concomitant boost radiotherapy","slug":"cetuximab-concomitant-boost-radiotherapy","indication":"Locally advanced head and neck squamous cell carcinoma (in combination with concomitant boost radiotherapy)","status":"phase_3"},{"name":"RNF","genericName":"RNF","slug":"rnf","indication":"Relapsed or refractory multiple myeloma","status":"phase_3"},{"name":"Tecemotide (L-BLP25)","genericName":"Tecemotide (L-BLP25)","slug":"tecemotide-l-blp25","indication":"Non-small cell lung cancer (NSCLC), stage IIIB/IV","status":"phase_3"},{"name":"cetuximab + cisplatin + vinorelbine","genericName":"cetuximab + cisplatin + vinorelbine","slug":"cetuximab-cisplatin-vinorelbine","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"cisplatin + vinorelbine","genericName":"cisplatin + vinorelbine","slug":"cisplatin-vinorelbine","indication":"Non-small cell lung cancer","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"Gabapentin/B-complex","genericName":"Gabapentin/B-complex","slug":"gabapentin-b-complex","indication":"Neuropathic pain (peripheral neuropathy, diabetic neuropathy)","status":"marketed"},{"name":"Rebif New Formulation + prophylactic Ibuprofen","genericName":"Rebif New Formulation + prophylactic Ibuprofen","slug":"rebif-new-formulation-prophylactic-ibuprofen","indication":"Relapsing-remitting multiple sclerosis (RRMS)","status":"phase_3"},{"name":"Interferon beta-1a (Rebif)","genericName":"Interferon beta-1a (Rebif)","slug":"interferon-beta-1a-rebif","indication":"Relapsing-remitting multiple sclerosis","status":"marketed"},{"name":"Rebif New Formulation + ibuprofen PRN","genericName":"Rebif New Formulation + ibuprofen PRN","slug":"rebif-new-formulation-ibuprofen-prn","indication":"Relapsing-remitting multiple sclerosis","status":"phase_3"},{"name":"Rebif® (clone 484-39)","genericName":"Rebif® (clone 484-39)","slug":"rebif-clone-484-39","indication":"Relapsing-remitting multiple sclerosis (RRMS)","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"rare","drugs":[{"name":"High Dose Bisoprolol","genericName":"High Dose Bisoprolol","slug":"high-dose-bisoprolol","indication":"Hypertension","status":"marketed"},{"name":"Low Dose Bisoprolol","genericName":"Low Dose Bisoprolol","slug":"low-dose-bisoprolol","indication":"Hypertension","status":"marketed"},{"name":"Sigmart (nicorandil)","genericName":"Sigmart (nicorandil)","slug":"sigmart-nicorandil","indication":"Angina pectoris (chronic stable angina and angina prophylaxis)","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Biltricide®","genericName":"Biltricide®","slug":"biltricide","indication":"Schistosomiasis (infection with Schistosoma species)","status":"marketed"},{"name":"Cysticide","genericName":"Cysticide","slug":"cysticide","indication":"Clonorchiasis due to C. Sinensis","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"Efalizumab (Raptiva)","genericName":"Efalizumab (Raptiva)","slug":"efalizumab-raptiva","indication":"Moderate to severe plaque psoriasis","status":"marketed"},{"name":"Systemic corticosteroids/methotrexate","genericName":"Systemic corticosteroids/methotrexate","slug":"systemic-corticosteroids-methotrexate","indication":"Rheumatoid arthritis","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"COL-1620","genericName":"COL-1620","slug":"col-1620","indication":"Idiopathic pulmonary fibrosis (IPF)","status":"phase_3"}]}],"pipeline":[{"name":"Colposeptine","genericName":"Colposeptine","slug":"colposeptine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Gabapentin/B-complex","genericName":"Gabapentin/B-complex","slug":"gabapentin-b-complex","phase":"marketed","mechanism":"Gabapentin reduces neuronal excitability by binding to the alpha-2-delta subunit of voltage-gated calcium channels, while B-complex vitamins support neuronal metabolism and myelin formation.","indications":["Neuropathic pain (peripheral neuropathy, diabetic neuropathy)","Postherpetic neuralgia","Adjunctive therapy for partial seizures"],"catalyst":""},{"name":"AS902330","genericName":"AS902330","slug":"as902330","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Biltricide®","genericName":"Biltricide®","slug":"biltricide","phase":"marketed","mechanism":"Praziquantel causes muscular paralysis and death of parasitic worms by increasing cell membrane permeability to calcium ions.","indications":["Schistosomiasis (infection with Schistosoma species)","Cysticercosis (Taenia solium infection)","Opisthorchiasis and clonorchiasis (liver fluke infections)","Other trematode and cestode infections"],"catalyst":""},{"name":"Cysticide","genericName":"Cysticide","slug":"cysticide","phase":"phase_1","mechanism":"Bile salt export pump, Glutathione S-transferase class-mu 26 kDa isozyme, High voltage-activated calcium channel beta subunit CavB1","indications":["Clonorchiasis due to C. Sinensis","Infection by Schistosoma","Opisthorchiasis","Schistosomiasis due to S. Haematobium","Schistosomiasis due to S. Japonicum"],"catalyst":""},{"name":"F0434","genericName":"F0434","slug":"f0434","phase":"phase_3","mechanism":"F0434 is an investigational immunotherapy agent designed to modulate immune responses, likely through checkpoint inhibition or T-cell activation pathways.","indications":[],"catalyst":""},{"name":"Follitropin beta liquid formulation","genericName":"Follitropin beta liquid formulation","slug":"follitropin-beta-liquid-formulation","phase":"phase_3","mechanism":"Follitropin beta is a recombinant human follicle-stimulating hormone (FSH) that stimulates the growth and maturation of ovarian follicles in women and spermatogenesis in men.","indications":["Infertility in women undergoing assisted reproductive technology (ART)","Infertility in men with hypogonadotropic hypogonadism"],"catalyst":""},{"name":"Gonalef® (Follitropin alfa)","genericName":"Gonalef® (Follitropin alfa)","slug":"gonalef-follitropin-alfa","phase":"phase_3","mechanism":"Follitropin alfa is a recombinant human follicle-stimulating hormone (FSH) that stimulates the growth and maturation of ovarian follicles in women.","indications":["Infertility in women undergoing assisted reproductive technology (ART)","Anovulation in women with polycystic ovary syndrome (PCOS)"],"catalyst":""},{"name":"IR Prednisone","genericName":"IR Prednisone","slug":"ir-prednisone","phase":"phase_3","mechanism":"IR Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","indications":["Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus, vasculitis)","Allergic reactions and asthma exacerbations","Adrenal insufficiency","Certain hematologic malignancies and lymphomas"],"catalyst":""},{"name":"Pergoveris®","genericName":"Pergoveris®","slug":"pergoveris","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rebif New Formulation + prophylactic Ibuprofen","genericName":"Rebif New Formulation + prophylactic Ibuprofen","slug":"rebif-new-formulation-prophylactic-ibuprofen","phase":"phase_3","mechanism":"Rebif (interferon beta-1a) activates interferon signaling pathways to modulate immune responses and reduce inflammation in the central nervous system, while prophylactic ibuprofen mitigates injection-site reactions and systemic inflammatory side effects.","indications":["Relapsing-remitting multiple sclerosis (RRMS)","Clinically isolated syndrome (CIS) with high risk of developing MS"],"catalyst":""},{"name":"Reference GIR","genericName":"Reference GIR","slug":"reference-gir","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Saizen® B","genericName":"Saizen® B","slug":"saizen-b","phase":"phase_3","mechanism":"Saizen B is a recombinant human growth hormone used to treat growth hormone deficiency.","indications":["Growth hormone deficiency in children"],"catalyst":""},{"name":"Urinary-hCG","genericName":"Urinary-hCG","slug":"urinary-hcg","phase":"phase_3","mechanism":"Urinary-hCG is a human chorionic gonadotropin (hCG) derived from urine that stimulates hormone production in reproductive tissues.","indications":["Hypogonadism in males","Infertility associated with hypogonadotropic hypogonadism","Ovulation induction in females with infertility"],"catalyst":""},{"name":"r-hGH","genericName":"r-hGH","slug":"r-hgh","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Analogous GnRH antagonist","genericName":"Analogous GnRH antagonist","slug":"analogous-gnrh-antagonist","phase":"phase_2","mechanism":"This GnRH antagonist blocks gonadotropin-releasing hormone receptors to suppress luteinizing hormone and follicle-stimulating hormone, reducing sex hormone production.","indications":["Advanced prostate cancer (hormone-sensitive)","Hormone-dependent breast cancer","Endometriosis","Uterine fibroids"],"catalyst":""},{"name":"COL-1620","genericName":"COL-1620","slug":"col-1620","phase":"phase_3","mechanism":"COL-1620 is a selective inhibitor of collagen-producing fibroblasts that reduces excessive collagen deposition in fibrotic tissues.","indications":["Idiopathic pulmonary fibrosis (IPF)"],"catalyst":""},{"name":"Cetrorelix acetate and Follitropin alfa","genericName":"Cetrorelix acetate and Follitropin alfa","slug":"cetrorelix-acetate-and-follitropin-alfa","phase":"phase_2","mechanism":"Cetrorelix acetate is a GnRH antagonist, and Follitropin alfa is a recombinant human FSH analogue.","indications":["Ovarian stimulation in assisted reproduction"],"catalyst":""},{"name":"Cetuximab + concomitant boost radiotherapy","genericName":"Cetuximab + concomitant boost radiotherapy","slug":"cetuximab-concomitant-boost-radiotherapy","phase":"phase_3","mechanism":"Cetuximab blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell growth, and when combined with concomitant boost radiotherapy, enhances radiation-induced cell death in cancer cells.","indications":["Locally advanced head and neck squamous cell carcinoma (in combination with concomitant boost radiotherapy)","Oropharyngeal cancer"],"catalyst":""},{"name":"Cisticid","genericName":"Cisticid","slug":"cisticid","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Efalizumab (Raptiva)","genericName":"Efalizumab (Raptiva)","slug":"efalizumab-raptiva","phase":"marketed","mechanism":"Efalizumab is a monoclonal antibody that blocks CD11a on T cells, preventing their activation and migration to the skin.","indications":["Moderate to severe plaque psoriasis"],"catalyst":""},{"name":"Follitropin alfa liquid formulation","genericName":"Follitropin alfa liquid formulation","slug":"follitropin-alfa-liquid-formulation","phase":"phase_3","mechanism":"Follitropin alfa is a recombinant human follicle-stimulating hormone (FSH) that stimulates ovarian follicle development and estrogen production in women.","indications":["Infertility in women undergoing assisted reproductive technology (ART) / in vitro fertilization (IVF)","Anovulation and ovulatory dysfunction in women"],"catalyst":""},{"name":"GONAL f® prefilled pen","genericName":"GONAL f® prefilled pen","slug":"gonal-f-prefilled-pen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GONAL-f®","genericName":"GONAL-f®","slug":"gonal-f","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GnRH antagonist","genericName":"GnRH antagonist","slug":"gnrh-antagonist","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Gonal -f® [r-hFSH]","genericName":"Gonal -f® [r-hFSH]","slug":"gonal-f-r-hfsh","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"High Dose Bisoprolol","genericName":"High Dose Bisoprolol","slug":"high-dose-bisoprolol","phase":"marketed","mechanism":"High-dose bisoprolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and cardiac contractility to lower blood pressure and improve cardiac function.","indications":["Hypertension","Angina pectoris","Heart failure with reduced ejection fraction","Post-myocardial infarction","Atrial fibrillation rate control"],"catalyst":""},{"name":"Interferon beta-1a (Rebif)","genericName":"Interferon beta-1a (Rebif)","slug":"interferon-beta-1a-rebif","phase":"marketed","mechanism":"Interferon beta-1a activates interferon signaling pathways to modulate immune responses and reduce inflammatory activity in the central nervous system.","indications":["Relapsing-remitting multiple sclerosis","Clinically isolated syndrome with MRI features consistent with multiple sclerosis"],"catalyst":""},{"name":"Kuvan®","genericName":"Kuvan®","slug":"kuvan","phase":"marketed","mechanism":"Kuvan is a synthetic form of tetrahydrofolate (BH4) that acts as a cofactor to restore phenylalanine ammonia-lyase (PAL) enzyme activity, enabling the metabolism of phenylalanine in patients with phenylketonuria.","indications":["Phenylketonuria (PKU) in patients with BH4-responsive mutations"],"catalyst":""},{"name":"Low Dose Bisoprolol","genericName":"Low Dose Bisoprolol","slug":"low-dose-bisoprolol","phase":"marketed","mechanism":"Bisoprolol is a beta-1 selective adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of catecholamines on the heart.","indications":["Hypertension","Chronic heart failure","Angina pectoris","Post-myocardial infarction"],"catalyst":""},{"name":"Luveris®","genericName":"Luveris®","slug":"luveris","phase":"marketed","mechanism":"Luveris is a recombinant human luteinizing hormone (LH) that stimulates ovarian steroid production and follicle development in women undergoing fertility treatment.","indications":["Infertility in women with profound LH deficiency undergoing assisted reproductive technology","Anovulation in women with hypogonadotropic hypogonadism"],"catalyst":""},{"name":"MSJ-0011","genericName":"MSJ-0011","slug":"msj-0011","phase":"phase_3","mechanism":"MSJ-0011 is an investigational immunotherapy that modulates immune checkpoint pathways to enhance anti-tumor immune responses.","indications":[],"catalyst":""},{"name":"Micronised Progesterone","genericName":"Micronised Progesterone","slug":"micronised-progesterone","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ovitrelle® [r-hCG alfa]","genericName":"Ovitrelle® [r-hCG alfa]","slug":"ovitrelle-r-hcg-alfa","phase":"marketed","mechanism":"Ovitrelle is a recombinant human chorionic gonadotropin (r-hCG) that binds to luteinizing hormone (LH) receptors to trigger final oocyte maturation and ovulation.","indications":["Final oocyte maturation induction in women undergoing assisted reproductive technology (ART) such as in vitro fertilization (IVF)","Ovulation induction in anovulatory women"],"catalyst":""},{"name":"Placebo - IR Prednisone","genericName":"Placebo - IR Prednisone","slug":"placebo-ir-prednisone","phase":"phase_3","mechanism":"This is a placebo control arm in a clinical trial; it contains no active pharmaceutical ingredient and produces no pharmacological effect.","indications":["Control arm in Phase 3 clinical trial of immediate-release prednisone"],"catalyst":""},{"name":"Placebo - MR Prednisone","genericName":"Placebo - MR Prednisone","slug":"placebo-mr-prednisone","phase":"phase_3","mechanism":"This is a placebo control, not an active drug, and therefore has no pharmacological mechanism of action.","indications":["Control arm in Phase 3 clinical trials of modified-release prednisone formulations"],"catalyst":""},{"name":"Placebo and Saizen®","genericName":"Placebo and Saizen®","slug":"placebo-and-saizen","phase":"phase_3","mechanism":"Saizen® is a recombinant human growth hormone that replaces or supplements endogenous growth hormone to promote growth and metabolic effects.","indications":["Growth hormone deficiency (likely indication based on Saizen® approved uses)","Short stature or growth disorders (potential Phase 3 indication)"],"catalyst":""},{"name":"RNF","genericName":"RNF","slug":"rnf","phase":"phase_3","mechanism":"RNF is a small molecule targeting the CD47/SIRPα axis.","indications":["Relapsed or refractory multiple myeloma","Relapsed or refractory non-Hodgkin lymphoma"],"catalyst":""},{"name":"Rebif New Formulation + ibuprofen PRN","genericName":"Rebif New Formulation + ibuprofen PRN","slug":"rebif-new-formulation-ibuprofen-prn","phase":"phase_3","mechanism":"Rebif (interferon beta-1a) activates interferon signaling pathways to modulate immune responses and reduce inflammation in the central nervous system.","indications":["Relapsing-remitting multiple sclerosis","Secondary progressive multiple sclerosis"],"catalyst":""},{"name":"Rebif® (clone 484-39)","genericName":"Rebif® (clone 484-39)","slug":"rebif-clone-484-39","phase":"marketed","mechanism":"Rebif is an interferon beta-1a that activates interferon receptors on immune cells to modulate immune response and reduce inflammation in the central nervous system.","indications":["Relapsing-remitting multiple sclerosis (RRMS)","Clinically isolated syndrome (CIS) with high risk of developing MS"],"catalyst":""},{"name":"Saizen® A","genericName":"Saizen® A","slug":"saizen-a","phase":"phase_3","mechanism":"Saizen A is a recombinant human growth hormone analogue used to treat growth hormone deficiency.","indications":["Growth hormone deficiency in children"],"catalyst":""},{"name":"Sigmart (nicorandil)","genericName":"Sigmart (nicorandil)","slug":"sigmart-nicorandil","phase":"marketed","mechanism":"Nicorandil opens ATP-sensitive potassium channels in vascular smooth muscle and also has nitrate-like vasodilatory properties, reducing cardiac preload and afterload.","indications":["Angina pectoris (chronic stable angina and angina prophylaxis)","Ischemic heart disease"],"catalyst":""},{"name":"Systemic corticosteroids/methotrexate","genericName":"Systemic corticosteroids/methotrexate","slug":"systemic-corticosteroids-methotrexate","phase":"marketed","mechanism":"This combination suppresses immune system activity through corticosteroid-mediated anti-inflammatory effects and methotrexate-induced immunosuppression via folate antagonism.","indications":["Rheumatoid arthritis","Systemic lupus erythematosus","Vasculitis","Other autoimmune inflammatory conditions"],"catalyst":""},{"name":"Tecemotide (L-BLP25)","genericName":"Tecemotide (L-BLP25)","slug":"tecemotide-l-blp25","phase":"phase_3","mechanism":"Tecemotide is a cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing MUC1 antigen.","indications":["Non-small cell lung cancer (NSCLC), stage IIIB/IV","Advanced or metastatic non-small cell lung cancer"],"catalyst":""},{"name":"cetuximab + cisplatin + vinorelbine","genericName":"cetuximab + cisplatin + vinorelbine","slug":"cetuximab-cisplatin-vinorelbine","phase":"phase_3","mechanism":"Cetuximab targets the epidermal growth factor receptor (EGFR), while cisplatin and vinorelbine work by interfering with DNA replication and cell division.","indications":["Metastatic colorectal cancer","Head and neck cancer"],"catalyst":""},{"name":"cisplatin + vinorelbine","genericName":"cisplatin + vinorelbine","slug":"cisplatin-vinorelbine","phase":"phase_3","mechanism":"Cisplatin and vinorelbine work together as a chemotherapy combination to kill cancer cells by damaging DNA and disrupting microtubule formation.","indications":["Non-small cell lung cancer","Ovarian cancer","Breast cancer"],"catalyst":""},{"name":"urinary hCG (u-hCG)","genericName":"urinary hCG (u-hCG)","slug":"urinary-hcg-u-hcg","phase":"phase_3","mechanism":"Urinary hCG is a diagnostic test that detects the presence of human chorionic gonadotropin in urine.","indications":["Pregnancy confirmation"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQODhTMHNrdVFuUnR4V1JGUnNRb3c2WlBNWl9aYmFnRlEyR3M2YXRRS0t1WENqaEN4TjlMSmFEZnZic3V2UHBCaEhfTW5vUUZUNlNvN0d0M0ZHazc2QWp0LWZvUnhJaU5uemxxQ1pMMU91X3h5ellYMDBpY2dma1RPNE1RNEQxNU5PenE4aFRsTDluLWkycEpaSHFOZkpnU0FnTk80M1ZvMnN6VTA4UFZpMFpYOE1jX0k0TS1TaDAydHJIWDA?oc=5","date":"2026-03-27","type":"pipeline","source":"AD HOC NEWS","summary":"Merck KGaA Stock: Navigating 2026 Guidance Challenges Amid Pharma Sector Pressures - AD HOC NEWS","headline":"Merck KGaA Stock: Navigating 2026 Guidance Challenges Amid Pharma Sector Pressures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOcmFhNG5kd0w3MF95amxLVzMwUG9YNUd0S294aG9GTjRoSGFWWU05cURxN2JSR1BaYVFDZlBoX1g3bHVYUDFteVExbGV6UUdXdDlRRkM3Z0o0Z3ZSRC15WS1nTzNVeVYwU2ZvSnhkeE1hWUxhbm5iS2c0LWxTaUY0UGNFLTZ3MjYtVi10NWVwbDY?oc=5","date":"2025-11-14","type":"regulatory","source":"Semafor","summary":"Belén Garijo’s prescription for Germany’s Merck - Semafor","headline":"Belén Garijo’s prescription for Germany’s Merck","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQeko4LTZ2QklVeEd5ekxwR2JwQi1HWmZWU0R0alczMXd6NC1mQmpHdFlQcVhRWC1RcXdqOG5ianpib3FmTmlHMERHaEZZSW5Edk9mTTBRc01HakZ3SXhPMHhLVlhGMmM1dG1TVG5vd0cxQ2Z4V0ZsRmNMYU5GengtQ2ZUc1dCQ3NCQ3NESWpOdlQ0LXAzdGhDRWNGQU9iX2YwVlFlY04ydVZOVHI4OW8zQTR3dHFQTlBRS29n?oc=5","date":"2025-11-13","type":"regulatory","source":"WSJ","summary":"Germany’s Merck KGaA Shares Rise After Semiconductor, Pharma Demand Boost Results - WSJ","headline":"Germany’s Merck KGaA Shares Rise After Semiconductor, Pharma Demand Boost Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNRV9wVG1jb292U1hHZnNyOEVrWWlvd0NVOUNMVmtqU0VhX2FjR3RMaVhzVV91U01CdFhmOVpMWDZaZnN2Q0JaSHN1cUpMTFRaR3lYVUhnVkVELVZJVlFkZldFbnQ0bVBhVU41SmxuMzE1ODNqTmEzQmpfOU1kWFVzWjRaZWJvejJtSHllWmw0aEdRQmlmODFhQ1RtWTI?oc=5","date":"2025-10-17","type":"pipeline","source":"European Biotechnology Magazine","summary":"Merck KGaA reduces US prices for IVF drugs by 84% - European Biotechnology Magazine","headline":"Merck KGaA reduces US prices for IVF drugs by 84%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQMXlRYWRFM2swd1JfUmFWVjkyV0N1LWxIR3B0ZWkxZFljVFFQN2U1VkpfUEJiX3FWc3BKeGxyZFNxeUtZU2tfWTJWQzZhMGFnMzB1cHRmVnZ2UHB1cTBXZWR4NlNYZ1YzQ29rNG00Y3JWMTQ0ekw4THZjeDc3ZXR3QW9rbmUwaDZMSk9iWDY4QnRsN2JkbEpSbnQ3MzAxTm9kZHhUME9YUUZnNmZ2eVFFWXFtYTFqQQ?oc=5","date":"2025-10-17","type":"deal","source":"Fierce Pharma","summary":"Merck KGaA's EMD Serono strikes MFN deal in Trump's fertility treatment pricing push - Fierce Pharma","headline":"Merck KGaA's EMD Serono strikes MFN deal in Trump's fertility treatment pricing push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNN2NkeUttc2FXUDI5ZkNlWG5YX1lDOUxXZy1IdWNGYkFweWt1dnMxWnF5UFhUMHdFYU95RFRIeURZRTVoZXg2SjNBN3VvVXFzQjJVN0IxeTVEMldvTHpfbXZCcVBqUjRMNDJTNHBpLUc1bEFkR0ZwRkRBeWg5bXRNREVkUFQ3VFJreVVsbDJIczVZbHV0M01EcUtjRUU3QzJCc3FTeG1PVUtCeEhtLVItckViUUZ4bWZKd2czM0pTUHVwOG9yQUE?oc=5","date":"2025-10-16","type":"deal","source":"reuters.com","summary":"Germany's Merck eyes life science deals, but muted 2026 outlook knocks shares - reuters.com","headline":"Germany's Merck eyes life science deals, but muted 2026 outlook knocks shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1QRGdNMWJ6R0Z1dmg3bmJBZmtjZS1namlVYkJFRXlnZnN0YThfbzY5MXdSTmZvWmtzVnZJZjRoWExtMlo3amdlT0ktRVI3cDFwU0lYRzhFWlVnMnpjZkZHbmJqVHVMS2lwWlA5U2xEXzYtOUdma1VKQk5qdTBtdw?oc=5","date":"2025-09-17","type":"deal","source":"China Daily","summary":"Merck aims to partner with pharma innovators - China Daily","headline":"Merck aims to partner with pharma innovators","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPMjNXNWhxMlBvTmF3eWs5WEJzS1JMNms4QlhCb3l1aDdjZEh3NGxESEhWV0xaaWIxbWFVWHhRTWdjWGJPZ3pvYUFKcU5Cd3NyRzU3MGpzR2NjR0t2WTFZR1lqbDg1eW1DLUFlZDQyUk1UMUl0SmE0SUU1RDhrbC01SGdnNkVFYjVCaE80WGMxdXlERE1ERWVLRTBjWHd1emd5TWhjQ2JQdmtNVm9FRFpfQzh2N2pieG4wTmxaZkxCejdtZmJMU2VxbkdhOU91OGE5aC1RSjNnajg?oc=5","date":"2025-09-02","type":"pipeline","source":"Contract Pharma","summary":"Merck KGaA, Darmstadt, Germany Names New Global Head of R&D and CMO for Healthcare Business Sector - Contract Pharma","headline":"Merck KGaA, Darmstadt, Germany Names New Global Head of R&D and CMO for Healthcare Business Sector","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxQV3VKcFhiQ0hYcllMRDBGZlU1MllWMUhMd1czN0hQMnF0TlZ5dzI2bFREdGxzWXQxYVVHMUZLOTdIc2Voc0dKQ25RRlFqRm5tRU5iLTRCMVZmWGx0d1IxdDdFWUdEMks1NGNLMG5SNjlXMlNaUFZaVkNIMm91UU92M0R2akloWHdVQ1h4THdrUEdRN2xCQVMzR0RDYkR2eExXVnJXRDI0V19wYmpNXzJkTlczQzdrLVNsaGV3dzc0NmhYMEVJRENNRF84ZXdlYnU4U2tOcFo5NzJSM0REeXFxRjVkNU5INXlwUDRQNk9qbkYxU0lsdVJnOHBZU0ZlSGQzcGw5SXdkNHd6clp3NkxSTWE1dl9FUmVEdFlHVWhUc3FzSU1XSGg0RDVjbkhQeUppdFNDamtfdHY2d0hSTHM1eg?oc=5","date":"2025-08-18","type":"deal","source":"PR Newswire","summary":"Skyhawk Therapeutics Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders - PR Newswire","headline":"Skyhawk Therapeutics Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany to Discover Novel RNA-Targeti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNaWt1OWZZS1VmUUVJRWt3djlzcnAxcV94eGlGWENYbWRrMUp4amtnUUkxUHBqWmYyQ0pZMHo2RlVFZl9tVUdoSnRKY2NhTnhDM0xIXzJac1JzVUloOEZ5TDZrVVA1SzdVbmlNZkdZbGhXcFNYVGRiVk1fczBiUEQ0VnJ3RGFJblVZ?oc=5","date":"2025-08-15","type":"pipeline","source":"Pharma Voice","summary":"Merck KGaA ventures into new territory in the US - Pharma Voice","headline":"Merck KGaA ventures into new territory in the US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPVDg4QkVpM2tiZkhPVXVGUHk2UWc0TENnUjRYY1R0Q3JidGVfSUwzVTdJQ2dQUm9GQWNvbjd4YmttWDFTWXJ6MnBQZnFTd2s3Z0Q5RndJWGNQSzBnaHRmOUZ3Wk5SNGx5cHA4Q2I0TXYyV2huODQ4d09oRVVUR2VsS0xJMDdoRFVLOHNmZFBmMjZidk0wY29iWTE0bVFWNzVJcUcyWGtLRElLQzNkZXA1MWVrdDNYWWxS?oc=5","date":"2025-07-01","type":"deal","source":"Contract Pharma","summary":"Merck KGaA, Darmstadt, Germany Acquires SpringWorks Therapeutics for $3.4M - Contract Pharma","headline":"Merck KGaA, Darmstadt, Germany Acquires SpringWorks Therapeutics for $3.4M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPb0ZXLUoxMmN0cl9rNHZmUVNDNXE3S3FESjllTGVtV2JtQzEtT01QaFdHTWxvcXRFZ1hQYjJHdDlEelBFay03QzBWVmw3ZHJWdUJ2eTVrVTM4UmxtaG5JS0Zxc2Y5U1hHdmNrSlZ4ZURaLUZCRW9RVW1odVJiem9zaTJPYw?oc=5","date":"2025-07-01","type":"pipeline","source":"Yahoo Finance","summary":"German pharma giant Merck takes over US cancer specialist - Yahoo Finance","headline":"German pharma giant Merck takes over US cancer specialist","sentiment":"neutral"}],"patents":[],"drugCount":47,"phaseCounts":{"marketed":19,"phase_1":4,"phase_3":22,"phase_2":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}